Within the Transcatheter Aortic Valve Replacement Market , the transfemoral approach holds the largest share, reflecting its status as the preferred and most minimally invasive route for TAVR. In the transfemoral approach, the delivery catheter is inserted through the femoral artery in the groin and advanced to the heart. This approach avoids the need for a chest incision, resulting in faster recovery, less pain, and fewer complications. The transfemoral approach is suitable for the majority of TAVR patients.

While the transfemoral approach dominates, transapical and direct access approaches are used for patients who are not suitable for transfemoral access due to peripheral artery disease, severe calcification, or other anatomical challenges. In the transapical approach, the delivery catheter is inserted through a small incision between the ribs and into the apex of the left ventricle. This approach provides a direct, short route to the aortic valve. In direct access (or transaortic) approach, the catheter is inserted through a small incision in the chest directly into the aorta.

The transapical and direct access approaches are more invasive than the transfemoral approach and are associated with longer recovery times and higher complication rates. However, they provide a valuable alternative for patients who cannot undergo transfemoral TAVR. The development of newer, smaller delivery systems is reducing the need for alternative access routes.

The growth of the transfemoral approach is driven by its minimally invasive nature and the development of smaller, more flexible delivery systems that can be used in patients with smaller or more tortuous arteries. The availability of alternative access routes ensures that TAVR can be offered to a broader range of patients, including those with complex anatomy.

The segmentation by access route highlights the importance of a tailored approach to TAVR. The choice of access route depends on a careful assessment of the patient's anatomy and risk factors. The transfemoral approach is preferred whenever possible, but alternative routes are essential for providing TAVR to all eligible patients. As technology continues to advance, the proportion of patients eligible for transfemoral TAVR is expected to increase.